Trevi Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release form of nalbuphine that acts on opioid receptors in the cough reflex arc to treat chronic cough. Its lead program targets chronic cough tied to idiopathic pulmonary fibrosis, with additional programs for other interstitial lung diseases and refractory chronic cough. The company has kept worldwide commercial rights to Haduvio.
Bought 5.43M
Bought 5.43M
Bought 5.43M
Bought 5.43M
Bought 5.43M
Bought 5.43M
Bought 4.48M
Bought 4.48M
Bought 5.43M
Sold 1.00M
Granted 948.9K
Granted 4.6K · Sold 4.6K
Granted 110.0K · Sold 104.0K
Granted 96.1K · Sold 96.1K
Granted 137.6K · Sold 81.3K
Granted 67.9K · Sold 18.6K
Granted 19.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Behbahani Ali10% owner · 4 transactions | +27.4% | 13.22M | — | 5.43M | — |
| Chang Carmen10% owner · 4 transactions | +27.4% | 13.22M | — | 5.43M | — |
| Florence Anthony A. Jr.10% owner · 4 transactions | +27.4% | 13.22M | — | 5.43M | — |
| Makhzoumi Mohamad10% owner · 4 transactions | +27.4% | 13.22M | — | 5.43M | — |
| Sandell Scott D10% owner · 4 transactions | +49% | 13.22M | — | 5.43M | — |
| Walker Paul Edward10% owner · 4 transactions | +49% | 13.22M | — | 5.43M | — |
| Baskett Forest10% owner · 3 transactions | +106.7% | 12.27Mas of Apr 2025 | — | 4.48M | — |
| Nea 16 GP, LLC +2 co-filers10% owner · 3 transactions | +106.7% | 12.27Mas of Apr 2025 | — | 4.48M | — |
| Sonsini Peter W.10% owner · 3 transactions | — | 11.37Mas of Apr 2022 | — | 5.43M | — |
| Bonderman David +3 co-filersFormer 10% Owner · 7 transactions | — | 3.82Mas of Jul 2022 | — | — | 1.00M |
| Mathers Edward TDirector · 1 transaction | — | 948.9Kas of Apr 2022 | 948.9K | — | — |
| Meeker David PDirector · 2 transactions | 0% | 352.5Kas of Aug 2024 | 4.6K | — | 4.6K |
| Sciascia ThomasChief Scientific Officer · 12 transactions | +15.6% | 224.0Kas of Mar 2025 | 110.0K | — | 104.0K |
| Good Jennifer LPresident & CEO, Director · 16 transactions | +3.4% | 213.3Kas of Mar 2025 | 96.1K | — | 96.1K |
| Simon FarrellChief Commercial Officer · 7 transactions | — | 81.3Kas of Mar 2025 | 137.6K | — | 81.3K |
| Delfini LisaChief Financial Officer · 22 transactions | — | 64.7Kas of Jan 2025 | 67.9K | — | 18.6K |
| Galletta ChristopherSee Remarks · 2 transactions | — | 26.1K | 19.2K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +45.69M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.